By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > News > ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
News

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

Last updated: 16/06/2025 8:36 AM
Published: 16/06/2025
Share
SHARE

SHANGHAI, June 16, 2025 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation. The investigational therapeutic drug is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and above.

- Advertisement -

First Methylphenidate Combination Drug Poised to Benefit Patients in China

- Advertisement -

Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and convenience of administering for patients, making it a potential best-in-class ADHD therapeutic drug.

- Advertisement -

Pharmacokinetic Property: Biphasic Release for Rapid Onset and Whole-Day Symptom Control

- Advertisement -
  • Rapid onset: Immediate-release d-MPH ensures symptom relief within 30 minutes, offering fast control over core ADHD symptoms.
  • Extended control: SDX is metabolized slowly into d-MPH in intestine over time, ensuring up to 13 hours of therapeutic effect with reduced risk of evening rebound symptoms.
  • Stable Release Profile: Designed to support the full span of a patient’s day—from school or work to evening activities—Azstarys enhances adherence and minimizes sleep disruptions, suiting both pediatric and adult populations.

Abuse-Deterrent Design

- Advertisement -

Azstarys incorporates an inherent abuse-deterrent design through the inclusion of SDX, which undergoes slow conversion in the gastrointestinal tract. This limits peak plasma concentrations of d-MPH and significantly reduces the potential for misuse via non-oral routes—a key public health consideration in ADHD pharmacotherapy.

- Advertisement -

Robust Clinical Efficacy and Safety Confirmed in China Phase III Trial

- Advertisement -
  • In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy endpoints.
  • The study reported no drug related serious adverse events, affirming Azstarys’s favorable safety and tolerability profile, critical for long-term use in pediatric settings.

Transforming ADHD Treatment Paradigm in China

- Advertisement -

As the third-generation methylphenidate therapy, Azstarys delivers a new standard of care in ADHD management by integrating rapid onset and full-day symptom control into a single dose. Its future approval in China would mark the introduction of the first ADHD combination medication to the market, offering a better option for patients, families, and physicians.

- Advertisement -

Dr. Jim Wu, CEO of ArkBio, stated, 

- Advertisement -

“The acceptance of Azstarys’ NDA and its designation for Priority Review by the NMPA reflect regulatory authority’s favorable opinions in our science and clinical study results. ADHD remains critically underserved in China, and Azstarys is designed to directly meet the needs of patients who require both immediate symptom relief and sustained control. We are grateful to our investigators, trial participants, collaborators, and the NMPA for this milestone and we look forward to accelerating access to this important therapeutic in China market.”

- Advertisement -

Azstarys® is a registered trademark of Corium, LLC in the United States.

About ArkBio

- Advertisement -

ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and Azstarys (AK0901), an FDA-approvedADHD therapeutic drug. 

- Advertisement -

ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.

- Advertisement -

For more information about the company, please visit our website:www.arkbiosciences.com

- Advertisement -

Logo – https://mma.prnewswire.com/media/2516404/5367504/ArkBio_Logo.jpg

- Advertisement -

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/arkbios-new-drug-application-for-adhd-therapeutic-azstarys-accepted-and-granted-priority-review-by-china-nmpa-302481852.html

- Advertisement -
Pride@Godrej 2025: Beyond Symbolism, Empowering LGBTQIA+ Voices and Businesses
Tata Communications Paves Way for Amazon Web Services’ Advanced AI-Optimised Network in India
Seraphim Awarded ‘Top Performer’ in Kiwa PVEL’s 2025 PV Module Reliability Scorecard for Sixth Time
NYSE Content Advisory: Pre-Market update + Small business optimism improves
Chandigarh University Fulfills Dreams of 388 students for Study in USA, 59 students in Australia, 48 students in Canada & 13 students in UK
TAGGED:(adhd)acceptedandapplicationarkbio’sazstaryschinadrugforgrantednewnewsnmpapriorityreviewtherapeutic
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
The Olympic Studies Centre welcomes Moroccan National Olympic Committee as second partner of Olympic World Library Network
Esports

The Olympic Studies Centre welcomes Moroccan National Olympic Committee as second partner of Olympic World Library Network

TheNews Market
TheNews Market
07/07/2025
Tulip Innovation Obtains Additional Battery Patent Injunction against Sunwoda Group
MindHYVE.ai and DV8 Infosystems Sign MoU with KICTANet to Co-Develop Kenya’s National AI Policy
Marlin Equity Partners Closes Latest Fund Oversubscribed at Hard Cap
NYSE Content Advisory: Pre-Market update + Trump sets 35% tariff on Canada
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?